Organon’s Liptruzet Approved in China for Hypercholesterolemia Treatment
US-based Organon (NYSE: OGN) has announced that it has received market approval from the National...
Chronic disease
MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies
Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...
Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial
Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...
HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026
The Department of Health and Human Services (HHS) in the US has released a list...
Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance
Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...
Sinovation Secures Over RMB 100 Million in Series D+ Financing for Neurosurgery Innovations
Beijing-based Sinovation (Beijing) Medical Technology Co., Ltd., a leader in neurosurgery diagnosis, minimally invasive procedure...
Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...
Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ:...
Jiangsu Hengrui Pharmaceutials’ SHR-1209 for Hypercholesterolemia Accepted for NMPA Review
China-based Jiangsu Hengrui Pharmaceutials (SHA: 600276) has announced that a market filing for its Category...
CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890
The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s...
Shenzhen Abrobo Medical Robot Secures RMB 100 Million in Series A Financing for Robotic Development
Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series...
Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions
China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese...
Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with...
MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...
Transcenta Holdings’ TST002 Shows Positive Phase I Results for Bone Density in China
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...
Coherent Biopharma Secures $100 Million in Series B and B+ Financings for Clinical Pipeline
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared...
Omron Healthcare and JD Healthcare Form Partnership to Innovate Chronic Disease Management
At the China International Medical Equipment Fair (CMEF), Omron Healthcare, a leading provider of healthcare...
Jiangsu Nhwa Pharmaceutical Receives NMPA Approval for Olinvyk (Oliceridine) Injection
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a China-based pharmaceutical company, has announced that it...
Hasten Biopharm Acquires Commercial Rights to Rocephin in China from Roche
China-based Hasten Biopharmaceutical Co., Ltd has announced the acquisition of the commercial rights in China...
Anhui and Qinghai Provinces Update BMI Chronic Disease Drug Lists for Outpatient Reimbursement
The healthcare security bureaus of Anhui and Qinghai provinces in China have separately released notifications...